Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group’s stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk tolerance may find the IPO appealing.
Violent crypto attacks rise as criminals hunt bigger payouts
Physical attacks targeting cryptocurrency holders surged 33% globally in the first half of 2026, with losses soaring to $124 million. France emerged as the epicentre